Gold extends rise on Fed rate cut hopes, softer dollar
Spot gold rose 0.4% to $3,367.53 per ounce as of 0156 GMT. U.S. gold futures for December delivery added 0.3% to $3,416.70.
"Markets are pricing in the chance that the Fed cuts 50 basis points in September. So the dollar's weakening, gold's going up as a result, yields are also down," said Kyle Rodda, Capital.com's financial market analyst.
"The technical setup of gold looks really constructive. The trend still looks higher. We just basically need to see the market break through $3,400 level on a sustained basis."
The dollar languished near multi-week lows against its rivals, making gold less expensive for holders of other currencies. Benchmark U.S. 10-year Treasury yields held near a one-week low.
U.S. consumer prices roseonly marginally in July, strengthening expectations of a Fed rate cut next month, with Treasury Secretary Scott Bessent noting there is a good chance the central bank will opt for a 50 bps reduction.
Traders now see a cut on September 17 as a near certainty, according to data compiled by LSEG, and even lay around 6% odds on a super-sized half-point trim.
Non-yielding gold thrives in a low-interest-rate environment.
Investors are awaiting the U.S. economic data due later this week, including the U.S. Producer Price Index, weekly jobless claims and retail sales data for clues into the Fed's rate path.
On the geopolitical front, Ukrainian President Volodymyr Zelenskiy said he warned U.S. President Donald Trump ahead of his talks with Vladimir Putin that the Russian leader was "bluffing" about his desire to end the war.
Elsewhere, spot silver gained 0.3% to $38.59 per ounce, platinum added 0.1% to $1,340.55 and palladium rose 1.5% to $1,139.52.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
27 minutes ago
- CNBC
Why Wall Street kept sending the S&P 500, Nasdaq to fresh records this week
The stock market ended the week higher as Wall Street speculated on how a spate of economic releases would impact the Federal Reserve's next interest rate decision. The S & P 500 and Nasdaq both gained nearly 1% over the past five sessions. Both benchmark gauges hit several record closes this week, with the S & P 500 reaching the milestone on Tuesday, Wednesday, and Thursday. The tech-heavy Nasdaq closed at record highs on Tuesday and Wednesday. Both indexes hit all-time intraday highs on Friday but closed the session modestly lower. Inflation data Stocks were pushed much higher on Tuesday, which carried the week, after the July consumer price index showed inflation had cooled more than expected. This caused Fed rate cut expectations for September to rise. The stock market's run continued into Wednesday's session. On Thursday, however, stocks lost some momentum after July's producer price index indicated that wholesale inflation rose more than expected last month. Despite higher inflation figures, though, the market odds of a rate cut at the Fed's meeting next month didn't decrease by much, according to the CME FedWatch tool. A second Fed rate cut by the end of the year is also expected. Cisco's quarter Our focus was also on quarterly earnings Wednesday evening from Cisco Systems , the latest addition to the Club's portfolio. Cisco beat analysts' expectations for the top and bottom lines during its fiscal 2025 fourth quarter. The company experienced strong revenue growth within its networking business thanks to the boom in AI infrastructure spending. Orders within the networking business surpassed $800 million during the fiscal fourth quarter, bringing the total to more than $2 billion for fiscal 2025. That's double management's goal for the year. Still, shares slipped after the release due to the significant revenue miss in Cisco's security division. That didn't shake our conviction in the stock, though. The Club reiterated our buy equivalent 1 rating , and maintained our price target of $78. "In a market that rewards AI-exposed companies with lofty valuations, Cisco trades at a very reasonable high teens price-to-earnings multiple. That valuation is too cheap to us," Jeff Marks, director of portfolio analysis for the Club, wrote in his earnings analysis. Later in the week, commentary from one Wall Street firm sent Cisco stock lower again. Shares fell 5.5% on Friday after HSBC downgraded the stock to a hold rating from a buy, and lowered its price target to $69 from $73. Analysts viewed Cisco's quarterly report as lackluster and said more stock gains would be hard to come by. "Though the company reported more than USD2bn of AI infrastructure orders in FY25, strength seems to be getting offset by weakness elsewhere," HSBC wrote in a Thursday note to clients. Record highs Although Cisco stock had a tough week, many other portfolio names experienced big runs. In fact, five Club holdings reached record highs since Monday. In no particular order, here's a breakdown of each. Goldman Sachs briefly reached an all-time high Friday of $749.05. But shares then tumbled 2.2% into the close. BlackRock hit a record Wednesday of $1,171.89. The stock drifted lower to around $1,135 by Friday's close. Broadcom on Wednesday touched $317.35, its highest stock price ever. Nvidia shares jumped to a record of $184.48 on Tuesday. Meta Platforms stock climbed to an all-time high of $796.25 on Friday. Portfolio moves We executed three trades last week, including exiting one position entirely. First, we bought more shares of Starbucks and Palo Alto Networks on Monday after unreasonable sell-offs. On Thursday, we sold the rest of our small Coterra Energy position. It no longer made sense to invest in Coterra in the current economic environment. Jim Cramer talked about this at length during the Club's August Monthly Meeting. We didn't just buy and sell, though. The Club changed ratings on two portfolio names as well. A new piece of Wall Street research led us to downgrade Salesforce on Monday to a hold-equivalent 2 rating. Analysts at Melius Research came out with a note that outlined the headwinds that generative AI could have on software-as-a-service companies like Salesforce. Shares then popped nearly 4% on Friday after filings revealed that Jeff Smith's Starboard Value increased its stake in Salesforce by 47% during the second quarter. That renewed bets that activists will push for change again, as they did with success a couple of years ago. After two terrible weeks, the stock finished this week up almost 1%. Two sessions later, the Club double upgraded Eli Lilly shares to a buy-equivalent 1 rating after CEO David Ricks and other company insiders bought a significant amount of the slumping stock. Health-care stocks, which had been struggling as a sector, have gotten a boost over the past week or so. Lilly stock was our best performer this week, jumping 12%. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
4 hours ago
- Yahoo
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Key Points Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no margin for competitive disruption. 10 stocks we like better than Eli Lilly › Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money faster than the Fed. But here's what the bulls aren't telling you: The company's next-generation oral weight-loss pill just delivered a reality check, and a scrappy competitor is positioning itself to steal the most lucrative slice of the $100 billion obesity treatment market. At today's premium valuation, that's a risk investors can't afford to ignore. The obesity empire strikes back Lilly's second-quarter numbers read like a growth investor's fantasy. Revenue surged 38% to $15.56 billion, with Mounjaro generating $5.2 billion (up 68%) and Zepbound delivering $3.38 billion (up 172% in the U.S. alone). The company raised full-year guidance to a range of $60 billion to $62 billion in revenue, with earnings per share expected between $21.75 and $23. That's a 61% jump in quarterly earnings to $6.31 per share, powered by an impressive 85% gross margin. The incretin drug portfolio now accounts for over half of Lilly's total revenue, a concentration that amplifies any competitive threat. The ATTAIN-1 trial results had already cast a shadow over these stellar financials. Orforglipron, Lilly's much-anticipated oral GLP-1 pill, delivered 12.4% weight loss at its highest dose, or about 27 pounds for the average patient. The stock dropped 14% on the news, and for good reason: Novo Nordisk's (NYSE: NVO) Wegovy achieves 14% to 15% weight loss with injections, while experimental oral competitors like Novo's CagriSema are targeting 20%. This underperformance matters financially: It narrows Lilly's addressable oral market, weakens its mass-market capture strategy, and hands ammunition to payers pushing for lower reimbursement rates. The Viking invasion nobody sees coming Here's why Viking Therapeutics (NASDAQ: VKTX) represents the only viable near-term threat with a real shot at breaching Lilly's obesity moat. VK-2735 isn't just another GLP-1 -- it's a dual GLP-1/GIP agonist attacking the market from two angles. The subcutaneous formulation, now in Phase 3, could launch as early as 2027. The oral version, currently in Phase 2, gives Viking a second shot at the convenience-seeking patient population that Lilly is struggling to capture with orforglipron. The Phase 2 numbers back up the threat. The subcutaneous version delivered 14.7% weight loss with significantly cleaner tolerability than current options -- 95% of gastrointestinal side effects were mild or moderate. The oral version's Phase 1 data showed something even more intriguing: Weight loss persisted six days after the last dose, suggesting durability that could become a marketing differentiator. Viking is also exploring monthly dosing that would revolutionize patient compliance. But here's the killer insight: VK-2735 is perfectly positioned to capture the patients that Lilly's retatrutide can't hold. While retatrutide might deliver blockbuster weight-loss numbers, its triple-agonist mechanism comes with tolerability trade-offs that could drive discontinuations. Viking's cleaner profile targets the population with a body mass index of 30 to 38 -- the most profitable recurring-revenue segment that generates decades of prescriptions. These aren't the sickest patients; they're the volume players who want results without harsh side effects. Timing turns this from a threat to a crisis. VK-2735's subcutaneous version could launch around 2027, with an oral version potentially following in 2028 -- precisely when orforglipron would be struggling to gain traction with inferior efficacy. If a major pharma partner like Pfizer or Amgen steps in, the launch scale could rival Lilly's overnight. The valuation trap At 29 times forward earnings, Lilly's market cap bakes in an uninterrupted march toward obesity dominance. VK-2735's entry could disrupt that march years before the Street expects it. The market is essentially betting that Mounjaro and Zepbound maintain trajectory, orforglipron somehow overcomes its efficacy gap, and retatrutide delivers without causing mass patient discontinuations. Those are three separate high-stakes bets, all priced for perfection. With these treatments now accounting for over half of its revenue, any market share loss hits twice as hard. Each percentage point Viking captures doesn't just reduce growth -- it challenges the entire premium multiple. Lilly bulls might argue the company's deep pipeline justifies today's valuation, and the 38% revenue growth proves this machine knows how to monetize innovation. But the orforglipron disappointment reveals that even Lilly can't guarantee every pipeline bet pays off. With Novo already commanding a significant share and Viking developing a dual-formulation strategy that offers more flexibility than anything in Lilly's pipeline, the duopoly's days could be numbered. At today's premium valuation, there's minimal margin for error and zero room for surprise competition. For investors, the smartest move might be taking some profits on Lilly's incredible run and watching Viking's Phase 2 oral results in the second half of 2025 from the safety of the sidelines -- that's when the real disruption story might start to unfold. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 George Budwell has positions in Pfizer and Viking Therapeutics and has the following options: long January 2026 $55 calls on Viking Therapeutics, long January 2026 $60 calls on Viking Therapeutics, and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. was originally published by The Motley Fool Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
5 hours ago
- Yahoo
Bitcoin Rally Stalls on U.S. Inflation, Policy Whiplash: Crypto Daybook Americas
By James Van Straten (All times ET unless indicated otherwise)Bitcoin's (BTC) flirt with a record high $124,000 on Thursday was followed by a drop that led to it closing last weekend's CME gap at $117,600 after hotter-than-expected PPI inflation data and Treasury Secretary Scott Bessent's apparent flip-flop on bitcoin purchases for a strategic reserve. The gap occurs because CME hours for BTC futures don't match bitcoin's 24/7 trading. When the futures market is closed over the weekend, bitcoin's movements can create a discontinuity in prices on the CME chart. While filling the gap is a recurring pattern in market behavior, there's not guarantee it will take place. Bitcoin has now set four all-time highs in 2025. Importantly, the magnitude of pullbacks following these peaks has been shrinking. After it hit $109,000 in January, BTC fell 30% to $76,000 by April. In May, the $112,000 high was followed by a 12% drop in June. July's $123,000 peak led to a 9% decline. Most recently, August's $124,000 high has so far seen only a 7% percent pullback, though we're only one day in. Looking ahead, Friday's U.S. retail sales report is forecast at 0.7% month-over-month, which would mark the strongest reading since March. A stronger-than-expected number could further undermine expectations for a September rate cut. Further out, attention turns to the end of August when $12 billion in bitcoin options are set to expire on Deribit. The majority of open call options are concentrated between the $120,000 and $124,000 strike prices, suggesting that if bitcoin trades near these levels, it would align with the positioning of many derivatives traders. Stay alert! What to Watch Crypto Aug. 15: Record date for the next FTX distribution to holders of allowed Class 5 Customer Entitlement, Class 6 General Unsecured and Convenience Claims who meet pre-distribution requirements. Aug. 18: Coinbase Derivatives will launch nano SOL and nano XRP U.S. perpetual-style futures. Aug. 20: Qubic (QUBIC), the fastest blockchain ever recorded, will undergo its first yearly halving event as part of a controlled emission model. Although gross emissions remain fixed at one trillion QUBIC tokens per week, the adaptive burn rate will increase substantially — burning some 28.75 trillion tokens and reducing net effective emissions to about 21.25 trillion tokens. Macro Aug. 15, 3 p.m.: U.S. President Donald Trump and Russian President Vladimir Putin will meet in Alaska to discuss potential peace terms for the war in Ukraine. Aug. 15, 12 p.m.: Colombia's National Administrative Department of Statistics (DANE) releases Q2 GDP growth data. GDP Growth Rate QoQ Prev. 0.8% GDP Growth Rate YoY Est. 2.6% vs. Prev. 2.7% Aug. 15, 4 p.m.: Peru's National Institute of Statistics and Informatics releases June GDP YoY growth data. GDP Growth Rate YoY Est. 4.7 vs. Prev. 2.67% Aug. 18, 6 p.m.: The Central Reserve Bank of El Salvador releases July producer price inflation data. PPI YoY Prev. 1.29% Earnings (Estimates based on FactSet data) Aug. 15: Sharplink Gaming (SBET), pre-market Aug. 15: BitFuFu (FUFU), pre-market, $0.07 Aug. 18: Bitdeer Technologies Group (BTDR), pre-market, -$0.12 Token Events Governance votes & calls SoSoValue DAO is voting to allocate 5 million SOSO tokens for a Researcher Ecosystem Fund aimed at boosting top-tier crypto research through competitions and incentives, improving content quality, transparency and SOSO's utility. Voting ends Aug. 18. Uniswap DAO is voting to allocate $540,000 in UNI over six months to as many as 15 top delegates, with up to $6,000 a month based on voting activity, community engagement, proposal authorship and holding 1,000+ UNI. Voting ends Aug. 18 Aavegotchi DAO is voting on a Bitcoin Ben's Crypto Club Las Vegas sponsorship: a $1,000/month corporate membership (logo on sponsor wall, team access, newsletter feature, one branded meetup/month) or a $5,000, 90-day Graffiti Wall mural with promo. Voting ends Aug. 23. Unlocks Aug. 15: Avalanche (AVAX) to unlock 0.33% of its circulating supply worth $41.84 million. Aug. 15: Starknet (STRK) to unlock 3.53% of its circulating supply worth $18.12 million. Aug. 15: Sei (SEI) to unlock 0.96% of its circulating supply worth $18.94 million. Aug. 16: Arbitrum (ARB) to unlock 1.8% of its circulating supply worth $49.95 million. Aug. 18: Fasttoken (FTN) to unlock 4.64% of its circulating supply worth $91.6 million. Aug. 20: LayerZero (ZRO) to unlock 8.53% of its circulating supply worth $57.59 million. Aug. 20: Kaito (KAITO) to unlock 8.82% of its circulating supply worth $27.55 million. Token Launches Aug. 15: PublicAI (PUBLIC) launches on Bitget, Binance Alpha, KuCoin and LBank. Aug. 15: Pepecoin (PEP) launches on AscendEX. Conferences The CoinDesk Policy & Regulation conference (formerly known as State of Crypto) is a one-day boutique event held in Washington on Sept. 10 that allows general counsels, compliance officers and regulatory executives to meet with public officials responsible for crypto legislation and regulatory oversight. Space is limited. Use code CDB10 for 10% off your registration through Aug. 31. Day 4 of 7: Ethereum NYC (New York) Day 2 of 2: CryptoWinter '25 (Queenstown, New Zealand) Aug. 15: Bitcoin Educators Unconference (Vancouver) Aug. 17-21: Crypto 2025 (Santa Barbara, California) Aug. 18-21: Wyoming Blockchain Symposium 2025 (Jackson Hole) Aug. 21-22: Coinfest Asia 2025 (Bali, Indonesia) Token Talk By Oliver Knight The crypto market drop in the past 24 hours sparked around $1 billion worth of liquidations, with the majority occurring on ETH trading pairs, according to Coinglass data. Ether is trading back at $4,630 while a number of altcoins like TIA, CRV and OP all lost more than 7%. One asset, however, stood out: AERO rose 4.5% despite relentless waves of selling pressure and liquidations. AERO is the native token of decentralized exchange Aerodrome, which recently benefited from integration with Coinbase, allowing the exchange's customer base to trade directly on the DEX via the Coinbase app. Trading volume on Aerodrome jumped as a result, with $1.1 billion worth of crypto changing hands to mark the DEX's largest day since February, according to DefiLlama. Aerodrome is the largest native part of the Base ecosystem, with $612 million in total value locked (TVL). The only other protocols with a higher totals are Morpho and Aave, both of which are distributed across multiple blockchains while Aerodrome is on Base alone. Derivatives Positioning Open interest (OI) across top derivatives venues remains elevated, with bitcoin (BTC) sitting at $32.5 billion, just shy of its all-time high. Bitcoin OI is led by Binance ($13.8 billion) and Bybit ($9.3 billion). The elevated open interest is supported by steady gains in BTC three-month annualized basis, currently 8%-9% across all exchanges, according to Velo data. Compared with fourth-quarter 2024 levels of 15%, there is still room to grow. In options, implied volatility (IV) across different option maturities is upward sloping (contango), with near-term IV low at around 20% , Velo data show. The line rises toward 50% for maturities in mid 2026, a sign of increasing uncertainty further out. Looking at the past day's flows for puts vs calls, the ratio is 50:50, implying no extreme directional bias at the moment. Funding rate APRs across major perpetual swap venues are muted at around an annualized 5%-7%, pulling back from the elevated levels seen in the run up to bitcoin's record high on Thursday. This pattern suggests that the rally was largely spot driven, with an influx of shorts helping offset long demand. With funding now relatively low, there is room for fresh leveraged longs to enter the market, potentially adding momentum to the next move. Coinglass data shows $960 million in 24 hour liquidations, skewed 85% towards longs. ETH ($342 million), BTC ($162 million) and others ($116 million) were the leaders in terms of notional liquidations. Binance liquidation heatmap indicates $117,091 as a core liquidation level to monitor, in case of further price drops. Market Movements BTC is up 0.68% from 4 p.m. ET Thursday at $118,739.67 (24hrs: -1.67%) ETH is up 1.9% at $4,622.44 (24hrs: -1.58%) CoinDesk 20 is up 1.33% at 4,257.98 (24hrs: -2.78%) Ether CESR Composite Staking Rate is up 1 bp at 3.05% BTC funding rate is at 0.0082% (8.9976% annualized) on Binance DXY is down 0.37% at 97.89 Gold futures are up 0.16% at $3,388.50 Silver futures are down 0.52% at $37.87 Nikkei 225 closed up 1.71% at 43,378.31 Hang Seng closed down 0.98% at 25,270.07 FTSE is unchanged at 9,181.53 Euro Stoxx 50 is up 0.42% at 5,457.44 DJIA closed on Thursday unchanged at 44,911.26 S&P 500 closed unchanged at 6,468.54 Nasdaq Composite closed unchanged at 21,710.67 S&P/TSX Composite closed down 0.28% at 27,915.99 S&P 40 Latin America closed down 1.16% at 2,653.40 U.S. 10-Year Treasury rate is down 0.2 bps at 4.291% E-mini S&P 500 futures are unchanged at 6,493.75 E-mini Nasdaq-100 futures are down 0.2% at 23,883.00 E-mini Dow Jones Industrial Average Index are up 0.64% at 45,283.00 Bitcoin Stats BTC Dominance: 59.4% (-0.42%) Ether-bitcoin ratio: 0.03901 (1.5%) Hashrate (seven-day moving average): 908 EH/s Hashprice (spot): $58.40 Total fees: 4.33 BTC / $519,718 CME Futures Open Interest: 140,870 BTC BTC priced in gold: 35.7 oz. BTC vs gold market cap: 10.08% Technical Analysis Bitcoin dominance recently fell below the key historical level of 60%. In the past, such drops have often preceded significant altcoin rallies. However, given the current lack of a strong catalyst for a full-fledged altcoin season, the key question is the potential severity of the drop. The current level suggests that a selective or minor 'alt season' is underway. It does not yet imply a major, market-wide shift in the way previous cycles have. Crypto Equities Strategy (MSTR): closed on Thursday at $372.94 (-4.35%), unchanged in pre-market Coinbase Global (COIN): closed at $324.89 (-0.65%), +0.11% at $325.25 Circle (CRCL): closed at $139.23 (-9.1%), -1.61% at $136.99 Galaxy Digital (GLXY): closed at $28.57 (+0.81%), -0.25% at $28.50 Bullish (BLSH): closed at $74.63 (+9.75%), +1.73% at $75.99 MARA Holdings (MARA): closed at $15.75 (-0.69%), -0.13% at $15.73 Riot Platforms (RIOT): closed at $12.25 (+5.69%), -1.14% at $12.11 Core Scientific (CORZ): closed at $13.84 (-0.11%), -0.61% at $13.75 CleanSpark (CLSK): closed at $9.95 (-0.2%), +0.3% at $9.98 CoinShares Valkyrie Bitcoin Miners ETF (WGMI): closed at $26.97 (+5.76%) Semler Scientific (SMLR): closed at $35.13 (-1.24%), unchanged in pre-market Exodus Movement (EXOD): closed at $26.85 (-1.79%), +8.01% at $29 SharpLink Gaming (SBET): closed at $23.49 (-0.13%), -0.17% at $23.45 ETF Flows Spot BTC ETFs Daily net flows: $230.8 million Cumulative net flows: $54.97 billion Total BTC holdings ~1.29 million Spot ETH ETFs Daily net flows: $639.6 million Cumulative net flows: $12.75 billion Total ETH holdings ~6.27 million Source: Farside Investors Chart of the Day The total value locked (TVL) on yield-trading platform Pendle has surged past the $8 billion mark, representing a roughly 30% increase this month and positioning it as the ninth largest protocol by TVL. The majority of the growth has taken place on the Ethereum blockchain. A key factor driving growth is its close relationship with Ethena's stablecoin. Some 68% of Pendle's TVL is tied to USDe and sUSDe, making the protocol a direct proxy for the growth of Ethena's ecosystem and a bet on the continued expansion of high-yield, stablecoin-based strategies in the market. While You Were Sleeping Altcoin Season Could Begin in September as Bitcoin's Grip on Crypto Market Weakens: Coinbase Institutional (CoinDesk): Investor rotation into altcoins could accelerate in September, fueled by declining bitcoin dominance, better liquidity for alternative tokens and improving risk appetite, Coinbase Institutional's David Duong said. Circle to Offer 10 Million Class A Shares at $130 Each (CoinDesk): The stablecoin issuer is selling 2 million shares in a secondary offering, while insiders are offloading the other 8 million at over four times the price of the June IPO. Hong Kong Regulator Tightens Custody Standards for Licensed Crypto Exchanges (CoinDesk): The SFC set minimum standards for senior management responsibility, cold wallet operations, third-party wallet solutions and real-time threat monitoring after finding cyber and asset-protection weaknesses at some licensed platforms. Crypto Group Backed by Trump Sons Hunts for Bitcoin Companies in Asia (Financial Times): U.S.-based miner American Bitcoin, co-founded by Eric Trump, is reportedly pursuing listed firms in Japan and Hong Kong to convert into bitcoin-treasury vehicles, seeking to spark demand through stock-market exposure. China's Economy Slows Broadly Even as Exports Keep Rising (The New York Times): China's statistics bureau linked July's slowdown in retail sales, factory output and fixed-asset investment primarily to escalating trade frictions, which its chief economist characterized as protectionism and unilateralism. Japan's Economy Records Modest Growth Despite Trade Uncertainty (The Wall Street Journal): Second-quarter GDP rose 0.3%, but economists warn automakers' prolonged absorption of U.S. tariff costs could squeeze profits, curb wage growth and dent household spending. In the Ether Sign in to access your portfolio
